Hanmi Pharmaceutical
128940.KS · Bio
Korea's largest pharmaceutical company by revenue. Known for proprietary LAPSCOVERY long-acting platform technology, with multi-billion-dollar global licensing deals in obesity and diabetes therapeutics.
Latest news
Top Traders Buy Samsung, SK hynix on Chip Dip, Sell Hanmi Pharm
D&D Pharmatech to Unveil Muscle-Sparing Obesity Drug Data at U.S. Meeting
Genentech Expands Personalized Obesity Strategy With Hanmi's Muscle-Sparing Drug
Preserving Muscle While Cutting Fat: A Game Changer in the $97 Billion Obesity Market
Hanmi Licenses Obesity Drug to Genentech in $2 Billion Deal
Hankook's Lim Ju-hyun Bets on R&D, Lands $2.3 Billion Drug Deal
Korean Firms Disclose Major Contracts and Deals on the 24th
Hanmi Pharm Hits Ceiling on $2.3 Billion Obesity Drug Licensing Deal
Hanmi Licenses Muscle-Sparing Obesity Drug to Genentech in $2 Billion Deal
Top 5 Korean Drugmakers Boost R&D Spending, Chong Kun Dang Jumps 37%
Hanmi's China Unit Cannot Cut Ties With Founder-Linked Kori Group
JW Pharma Advances Biweekly Obesity Drug to Phase 3 as Long-Acting Race Heats Up
Hanmi, Yuhan Post Record Q2 Profit on Drug Licensing Deals
Hanmi Pharmaceutical CEOs, CFOs Make Joint China Trip Over Receivables
Court Freezes 10 Billion Won of Hanmi Science Shares Held by Lim Ju-hyun
Hanmi Group Launches Company-Wide AI Innovation Program
Hanmi's Obesity Drug Plant Wins Top Safety Grade for Second Time
Kori Group's Beijing Hanmi Payables Double Ahead of Hong Kong Listing
Wegovy Falls 20-Fold Behind Mounjaro in New Prescriptions, May Cut Prices Again
Hanmi Pharm Shares Have Priced In Excessive Concerns, Analyst Says
Beijing Hanmi Faces Potential 100 Billion Won Receivables Loss, Testing CEO Hwang
Hanmi Science Q2 Operating Profit Jumps 71% on Subsidiary Growth, Distribution Gains
